The Asia Pacific radiopharmaceuticals market size is expected to reach USD 5,532.66 million by 2034, according to a new study by Polaris Market Research. The report “Asia Pacific Radiopharmaceuticals Market Share, Size, Trends, Industry Analysis Report: By Type (Diagnostic and Therapeutic), Application, End Use, and Countries (China, Japan, India, Malaysia, South Korea, Indonesia, Australia, Vietnam, and Rest of Asia Pacific); Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Radiopharmaceuticals are specialized medicinal compounds that contain radioactive isotopes for disease diagnosis and targeted therapy. A major trend shaping the Asia Pacific radiopharmaceuticals market development is the growing shift toward theranostics, which integrates diagnostic imaging and targeted radiotherapy into a single approach. This advancement is improving precision medicine by allowing real-time disease assessment and personalized treatment strategies. The increasing focus on theranostics is driving demand for novel radiopharmaceuticals, improving patient outcomes, and expanding the clinical applications of nuclear medicine. Additionally, advancements in radioisotope production and radiolabeling techniques are strengthening the adoption of these advanced medical solutions.
The increasing adoption of artificial intelligence (AI) and automation in nuclear medicine is expected to emerge as a key Asia Pacific radiopharmaceuticals market trend. AI-driven imaging analysis and automated radiopharmaceutical synthesis are improving diagnostic accuracy, optimizing workflow efficiency, and reducing human error in radiotracer production. These technological advancements are improving the reliability and scalability of nuclear imaging, allowing faster and more precise disease detection. Thus, as healthcare providers and research institutions continue to integrate AI and automation into nuclear medicine, the market is witnessing a shift toward more efficient and cost-effective radiopharmaceutical solutions, further driving innovation and growth in the industry.
Asia Pacific Radiopharmaceuticals Market Report Highlights
In terms of type, the diagnostic segment led the Asia Pacific radiopharmaceuticals market share in 2024, fueled by the growing reliance on nuclear imaging for early disease detection and accurate diagnosis.
Based on end use, the hospitals and clinics segment is anticipated to experience the fastest growth during the forecast period, driven by increased investments in healthcare infrastructure and nuclear medicine facilities.
Japan accounted for the largest share of the Asia Pacific radiopharmaceuticals market revenue in 2024, supported by its advanced healthcare system, robust nuclear medicine infrastructure, and strong expertise in radiopharmaceutical research and development.
The radiopharmaceuticals market in India is expected to grow significantly during the forecast period, driven by rising healthcare investments, an increasing disease burden, and the expansion of nuclear medicine infrastructure.
A few global key market players include Bayer AG; Bracco Diagnostic Inc.; Cardinal Health; Curium Pharma; GE Healthcare; IBA Radiopharma Solutions; Lantheus; Nihon Medi-Physics Co., Ltd.; Nordion, Inc.; NTP; PDRadiopharma Inc.; Siemens Healthcare Private Limited; and Telix Pharmaceuticals Limited.
Polaris Market Research has segmented the Asia Pacific radiopharmaceuticals market report on the basis of type, application, end use, and region:
By Type Outlook (Revenue, USD Million, 2020–2034)
Diagnostic
Therapeutic
By Application Outlook (Revenue, USD Million, 2020–2034)
Cancer
Cardiology
Others
By End Use Outlook (Revenue, USD Million, 2020–2034)
Hospitals and Clinics
Medical Imaging Centers
Others
By Regional Outlook (Revenue, USD Million, 2020–2034)
Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- 1. Introduction
- 1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
- 1.2. Stakeholders
- 2. Executive Summary
- 2.1. Market Highlights
- 3. Research Methodology
- 3.1. Overview
- 3.1.1. Data Mining
- 3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources
- 4. Global Asia Pacific Radiopharmaceuticals Market Insights
- 4.1. Asia Pacific Radiopharmaceuticals Market – Market Snapshot
- 4.2. Asia Pacific Radiopharmaceuticals Market Dynamics
- 4.2.1. Drivers and Opportunities
- 4.2.1.1. Growing Prevalence of Cancer and Chronic Diseases
- 4.2.1.2. Increasing Adoption of Advanced Imaging Techniques
- 4.2.2. Restraints and Challenges
- 4.2.2.1. High Cost of Radiopharmaceuticals and Associated Treatments
- 4.2.3. Public opinion and privacy legal precedents
- 5. Porter’s Five Forces Analysis
- 5.1.1. Bargaining Power of Suppliers (Moderate)
- 5.1.2. Threats of New Entrants: (Low)
- 5.1.3. Bargaining Power of Buyers (Moderate)
- 5.1.4. Threat of Substitute (Moderate)
- 5.1.5. Rivalry among existing firms (High)
- 5.2. PESTEL Analysis
- 5.3. Asia Pacific Radiopharmaceuticals Market Trends
- 5.4. Value Chain Analysis
- 6. Global Asia Pacific Radiopharmaceuticals Market, by Type
- 6.1. Key Findings
- 6.2. Introduction
- 6.2.1. Global Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 6.3. Diagnostic
- 6.3.1. Global Asia Pacific Radiopharmaceuticals Market, by Diagnostic, by Region, 2020–2034 (USD Million)
- 6.4. Therapeutic
- 6.4.1. Global Asia Pacific Radiopharmaceuticals Market, by Therapeutic, by Region, 2020–2034 (USD Million)
- 7. Global Asia Pacific Radiopharmaceuticals Market, by Application
- 7.1. Key Findings
- 7.2. Introduction
- 7.2.1. Global Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 7.3. Cancer
- 7.3.1. Global Asia Pacific Radiopharmaceuticals Market, by Cancer, by Region, 2020–2034 (USD Million)
- 7.4. Cardiology
- 7.4.1. Global Asia Pacific Radiopharmaceuticals Market, by Methyl Asia Pacific Radiopharmaceuticals, by Region, 2020–2034 (USD Million)
- 7.5. Others
- 7.5.1. Global Asia Pacific Radiopharmaceuticals Market, by Others, by Region, 2020–2034 (USD Million)
- 8. Global Asia Pacific Radiopharmaceuticals Market, by End Use
- 8.1. Key Findings
- 8.2. Introduction
- 8.2.1. Global Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 8.3. Hospitals and Clinics
- 8.3.1. Global Asia Pacific Radiopharmaceuticals Market, by Hospitals and Clinics, by Region, 2020–2034 (USD Million)
- 8.4. Medical Imaging Centers
- 8.4.1. Global Asia Pacific Radiopharmaceuticals Market, by Medical Imaging Centers, by Region, 2020–2034 (USD Million)
- 8.5. Others
- 8.5.1. Global Asia Pacific Radiopharmaceuticals Market, by Others, by Region, 2020–2034 (USD Million)
- 9. Global Asia Pacific Radiopharmaceuticals Market, by Geography
- 9.1. Key Findings
- 9.2. Introduction
- 9.2.1. Asia Pacific Radiopharmaceuticals Market Assessment, By Geography, 2020–2034 (USD Million)
- 9.3. Asia Pacific Radiopharmaceuticals Market – Asia Pacific
- 9.3.1. Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.2. Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.3. Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.4. Asia Pacific Radiopharmaceuticals Market – China
- 9.3.4.1. China: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.4.2. China: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.4.3. China: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.5. Asia Pacific Radiopharmaceuticals Market – India
- 9.3.5.1. India: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.5.2. India: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.5.3. India: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.6. Asia Pacific Radiopharmaceuticals Market – Malaysia
- 9.3.6.1. Malaysia: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.6.2. Malaysia: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.6.3. Malaysia: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.7. Asia Pacific Radiopharmaceuticals Market – Japan
- 9.3.7.1. Japan: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.7.2. Japan: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.7.3. Japan: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.8. Asia Pacific Radiopharmaceuticals Market – Indonesia
- 9.3.8.1. Indonesia: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.8.2. Indonesia: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.8.3. Indonesia: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.9. Asia Pacific Radiopharmaceuticals Market – South Korea
- 9.3.9.1. South Korea: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.9.2. South Korea: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.9.3. South Korea: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.10. Asia Pacific Radiopharmaceuticals Market – Australia
- 9.3.10.1. Australia: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.10.2. Australia: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.10.3. Australia: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 9.3.11. Asia Pacific Radiopharmaceuticals Market – Rest of Asia Pacific
- 9.3.11.1. Rest of Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by Type, 2020–2034 (USD Million)
- 9.3.11.2. Rest of Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by Application, 2020–2034 (USD Million)
- 9.3.11.3. Rest of Asia Pacific: Asia Pacific Radiopharmaceuticals Market, by End Use, 2020–2034 (USD Million)
- 10. Competitive Landscape
- 10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
- 10.2. Partnerships/Collaborations/Agreements/Exhibitions
- 11. Company Profiles
- 11.1. Bayer AG
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
- 11.2. Bracco Diagnostic Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
- 11.3. Cardinal Health
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
- 11.4. Curium Pharma
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
- 11.5. GE Healthcare
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
- 11.6. IBA Radiopharma Solutions
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
- 11.7. Lantheus.
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
- 11.8. Nihon Medi-Physics Co., Ltd.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
- 11.9. Nordion, Inc.
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
- 11.10. NTP
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development
- 11.11. PDRadiopharma Inc.
- 11.11.1. Company Overview
- 11.11.2. Financial Performance
- 11.11.3. Product Benchmarking
- 11.11.4. Recent Development
- 11.12. Siemens Healthcare Private Limited
- 11.12.1. Company Overview
- 11.12.2. Financial Performance
- 11.12.3. Product Benchmarking
- 11.12.4. Recent Development
- 11.13. Telix Pharmaceuticals Limited.
- 11.13.1. Company Overview
- 11.13.2. Financial Performance
- 11.13.3. Product Benchmarking
- 11.13.4. Recent Development
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook